https://lgenia.com/news/ Latest updates on Lgenia's research in tuberculosis, malaria, Alzheimer's disease, and global health partnerships. en-us Wed, 30 Sep 2026 03:38:22 GMT https://lgenia.com/news/iu-alz-discovery-moves-forward/ https://lgenia.com/news/iu-alz-discovery-moves-forward/ Mon, 14 Jul 2025 04:00:00 GMT Indiana University School of Medicine researchers, in partnership with Lgenia, have identified a portfolio of novel drug targets that may accelerate promising treatments for patients living with Alzheimer’s disease. https://lgenia.com/news/africa-mentorship/ https://lgenia.com/news/africa-mentorship/ Tue, 14 Mar 2023 04:00:00 GMT In early 2022, the Gates Foundation awarded a grant to the University of Ghana, NMIMR, and KNUST to establish a collaborative drug discovery program. Lgenia mentored the Ghanaian team, and in February 2023, Dr. Miles Siegel visited Africa for a multi-institutional check-in. https://lgenia.com/news/tb-accelerator-10/ https://lgenia.com/news/tb-accelerator-10/ Fri, 10 Dec 2021 05:00:00 GMT The TB Drug Accelerator (TBDA) marks a decade of collaborative research, accelerating the discovery of new treatments for tuberculosis. Lgenia contributed to milestone studies, helping to identify promising compounds. https://lgenia.com/news/iu-alzheimers/ https://lgenia.com/news/iu-alzheimers/ Wed, 05 Aug 2020 04:00:00 GMT In 2020, Lgenia partnered with Indiana University to accelerate Alzheimer's research, combining expertise in medicinal chemistry and neurobiology. The collaboration aims to discover new therapies for patients. https://lgenia.com/news/tb-accelerator-join/ https://lgenia.com/news/tb-accelerator-join/ Tue, 22 May 2018 04:00:00 GMT In 2018, Lgenia joined the TB Drug Accelerator, a global partnership to fast-track the development of new tuberculosis treatments. Our team contributed to early-stage research and compound screening.